Rhythm Pharmaceuticals (MEX:RYTM) Construction In Progress: MXN0 Mil (As of Mar. 2026)


MEX:RYTM Rhythm Pharmaceuticals Inc MEX:RYTM
56 GF Score
Price MXN1,866.76
GF Value MXN1,874.87
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Construction In Progress?

Rhythm Pharmaceuticals MEX:RYTM 56 Construction In Progress is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:RYTM with a GF Score™ of 56/100 and a GF Value™ of MXN1,874.87. The stock has 3 warning signs investors should review.

Rhythm Pharmaceuticals's quarterly construction in progress increased from Sep. 2025 (MXN0 Mil) to Dec. 2025 (MXN17 Mil) but then declined from Dec. 2025 (MXN17 Mil) to Mar. 2026 (MXN0 Mil).

Rhythm Pharmaceuticals's annual construction in progress stayed the same from Dec. 2023 (MXN0 Mil) to Dec. 2024 (MXN0 Mil) but then increased from Dec. 2024 (MXN0 Mil) to Dec. 2025 (MXN17 Mil).

Rhythm Pharmaceuticals Construction In Progress Historical Data

* Premium members only.

The historical data trend for Rhythm Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals Construction In Progress Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 16.67

Rhythm Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 16.67 0.00
MEX:RYTM
56GF Score
Rhythm Pharmaceuticals Inc MEX:RYTM
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of MXN0 Mil mean?
Rhythm Pharmaceuticals (MEX:RYTM) has a Construction In Progress of MXN0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Rhythm Pharmaceuticals and its competitors.
Is Rhythm Pharmaceuticals' Construction In Progress too high?
Rhythm Pharmaceuticals' current Construction In Progress is MXN0 Mil. Overall, Rhythm Pharmaceuticals has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Construction In Progress compare to MIRM and SYRE?
Rhythm Pharmaceuticals' Construction In Progress of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Construction In Progress is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Rhythm Pharmaceuticals (MEX:RYTM) has a current Construction In Progress of MXN0 Mil. The stock's GF Value™ is MXN1,874.87, compared to a current price of MXN1,866.76 — trading 0.4% below its estimated fair value. The current Construction In Progress is MXN0 Mil. Rhythm Pharmaceuticals' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Rhythm Pharmaceuticals (MEX:RYTM), the current Construction In Progress is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rhythm Pharmaceuticals (MEX:RYTM) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued. The current stock price of MXN1,866.76 is trading 0.4% below its estimated GF Value™ of MXN1,874.87.

Key valuation signals for MEX:RYTM:

  • Construction In Progress: MXN0 Mil
  • GF Value™: MXN1,874.87 vs. price of MXN1,866.76 (0.4% below fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the MEX:RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rhythm Pharmaceuticals Business Description

Other Exchanges RYTM:USA1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
56GF Score

Get the complete analysis for MEX:RYTM

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,866.76
Price
MXN1,874.87
GF Value